CGON
CG Oncology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
CGON Profile
Cg Oncology, Inc.
A late-stage clinical biopharmaceutical company focused on treating bladder cancer
400 Spectrum Center Drive, Suite 2040 Irvine, CA 92618
--
CG Oncology, Inc., originally established on September 24, 2010, is a California corporation named Cold Genesys, Inc. On November 30, 2017, the Company was re-registered as a Delaware corporation, and on March 31, 2020, the Company was renamed CG Oncology, Inc. The Company is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder retention therapy for patients with bladder cancer. The company's product candidate, cretostimogene, is initially in clinical development for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC) patients who have not responded to BCG therapy, which is the current standard of care for high-risk NMIBC. Given the limitations of currently approved therapies and the reluctance of patients to undergo radical cystectomy or complete bladder resection, there is a significant unmet need for these patients. The company is evaluating the safety and efficacy of cretostimogene as a monotherapy in BOND-003, and the company is conducting a Phase 3 clinical trial in high-risk BCG non-responsive NMIBC patients. The company has completed registration for the trial, reporting interim data in November 2023 and expects to report top-line data by the end of 2024.